NCT06374264View on ClinicalTrials.gov

Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder

NAEnrolling by invitationINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 12, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions
Neuromyelitis Optica Spectrum Disorder
Interventions
DEVICE

MR-C-014

Use of device 3 times per week (for 30 minutes) for 8 weeks - for a total of 24 sessions.

Trial Locations (2)

30309

Sheperd Center, Atlanta

02114

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
collaborator

Alexion Pharmaceuticals, Inc.

INDUSTRY

lead

MedRhythms, Inc.

INDUSTRY